People

Services

Industries

Firm

About

Knowledge

Careers

News

Events

Contact

Connect

Privacy Policy

Disclaimer

Terms of Use

Accessibility

Payments

Legal

Calgary

Toronto

Edmonton

Ottawa

Vancouver

New York

Montréal

Ahmed Elmallah

Intellectual Property Lawyer at Bennett Jones Edmonton

Counsel, Patent Agent, Trademark Agent

Roseann Caldwell

Canadian and United States Patent Agent at Bennett Jones Calgary

Patent Agent

Stephen D. Burns

Energy & Infrastructure Technology Lawyer | IT/OT & Markets

Partner, Trademark Agent

This update analyzes recent Patent Appeal Board decisions to identify trends in the allowance of fintech and financial services patents in Canada. It shows that patentable claims typically frame innovations as technical solutions&mdash;such as improving computing efficiency or integrating specialized hardware&mdash;rather than purely business methods. These trends align with post-Dusome guidance and provide practical insight into how fintech inventions can meet patent eligibility requirements.

Fintech Patents Allowance Trends At The Canadian Patent Appeal Board

Part 2 Fintech Patents: Allowance Trends At The Canadian Patent Appeal Board

This update reviews the Federal Court&rsquo;s *Dusome* decision and CIPO&rsquo;s new guidance on patent eligibility for computer-implemented inventions in Canada. It highlights a shift toward purposive claim construction and clarifies that fintech innovations may be patentable where they demonstrate a practical application or improve computer functionality. The guidance offers greater predictability for applicants, particularly in financial technology contexts.<br />
<div>&nbsp;</div>

Fintech Patents New Eligibility Guidance In Canada

Part 1 Fintech Patents: New Eligibility Guidance In Canada

Benjamin K. Reingold

Intellectual Property Litigation Lawyer at Bennett Jones Calgary

Partner

Melissa M. Dimilta

Intellectual Property Lawyer at Bennett Jones Toronto

Lorelei Graham

IP Lawyer | Food & Agribusiness

This blog examines why Canada&rsquo;s Federal Court is the preferred venue for pharmaceutical patent litigation. It highlights its specialized expertise, efficient procedures and consistent, precedent-driven decisions.

Northern Advantage Canadas Federal Court as a Venue for Pharmaceutical Patent Litigation

Northern Advantage: Canada's Federal Court as a Venue for Pharmaceutical Patent Litigation

This four-part AI Insights Quick Read series explores how routine generative AI use can expose confidential information, weaken privilege and erode intellectual property value. Using US v. Heppner as a starting point, it examines disclosure risk, shadow AI, content dilution and key implications for Canadian organizations.

Part 2 Shadow AI The Unmanaged Use That Creates Real IP Disclosure Risk

Part 2 of the AI Insights and Fast Reads Series

Shadow AI: The Unmanaged Use That Creates Real IP Disclosure Risk

Michelle F. Yung

Real Estate Lawyer at Bennett Jones Vancouver

Luke Stretch

Commercial Real Estate Lawyer at Bennett Jones Calgary

Associate

Nathalie Hunter

Articling Student at Bennett Jones Vancouver

Articling Student

In <em>Convocation Flowers Incorporated v. Anisa Holdings Ltd.</em>, 2026 ONCA 145, the Ontario Court of Appeal held that a landlord&rsquo;s interference with essential common area access&mdash;specifically loading dock facilities&mdash;can constitute a repudiatory breach of a commercial lease. The Court emphasized that even broadly drafted landlord discretion clauses cannot be exercised in a way that defeats a tenant&rsquo;s core operational use of the premises. The decision reinforces that courts will assess lease performance in practical, commercial terms when determining whether a fundamental breach has occurred.

Repudiation by Denied Access

Convocation Flowers Incorporated v. Anisa Holdings Ltd., 2026 ONCA 145

Repudiation by Denied Access: ONCA Confirms Loss of Essential Common Area Access May Be Repudiatory Breach of Lease

Vincent M. de Grandpré

IP Lawyer | Life Sciences & Tech

As part of a deeply interconnected global sector, the life sciences industry in Canada is undergoing significant change alongside broad macroeconomic and geopolitical shifts.&nbsp;The Bennett Jones Life Sciences team looks at the top issues and developments affecting the industry in 2026.

2026 Life Sciences Outlook

Legal and Market Trends to Watch This Year

Life Sciences Outlook 2026

Aaron E. Sonshine

Corporate Finance, Mergers and Acquisitions and Corporate Governance Lawyer at Bennett Jones Toronto

Partner 

The life sciences sector is experiencing a renewed wave of M&amp;A activity driven by patent expiries, expanding investor appetite and growing demand for innovative therapies and technologies. Drawing on insights shared at the Bloom Burton &amp; Co. Healthcare Investor Conference, this update explores the key trends shaping dealmaking in Canada and globally, including increased competition for assets, rising private transactions and growing investment in emerging markets such as China. The author also examines why current market conditions point to continued momentum across the sector in the second half of 2026.

The Life Sciences Boom

The Life Sciences Boom: H2 2026 Outlook

Alison G. FitzGerald

International Arbitration Lawyer at Bennett Jones Ottawa

Quinn Scarlett

Commercial Litigation and Arbitration Lawyer at Bennett Jones Toronto

In Grace et al v. The United Mexican States, the Ontario Superior Court set aside a NAFTA arbitral award on both jurisdictional and arbitrator impartiality grounds, marking a significant development in Canada&rsquo;s international arbitration jurisprudence. The decision clarifies Ontario courts&rsquo; willingness to conduct rigorous review of jurisdictional determinations, scrutinize arbitrator disclosure obligations, and preserve meaningful protections for minority investors and dual nationals in investor-state disputes.<br />
<div>&nbsp;</div>

Ontario Court Sets Aside ICSID Award in NAFTA Arbitration

Ontario Court Sets Aside ICSID Award in NAFTA Arbitration: Key Lessons on Jurisdiction and Arbitrator Impartiality

Emma Danaher

Commercial Litigation Lawyer at Bennett Jones Toronto

Associate 

Canada is advancing regulatory modernization through reforms aimed at improving efficiency, reducing duplication, and aligning with global standards. Key initiatives include streamlined biosimilar approval requirements, a proposed foreign reliance pathway for drug approvals, and amendments to medical device regulations. Together, these changes are expected to lower costs and accelerate market access for life sciences companies starting in 2026 and beyond.

Stephen Burns in Lexpert

From the Same Authors

Fintech Patents: Allowance Trends At The Canadian Patent Appeal Board

Fintech Patents: New Eligibility Guidance In Canada

Northern Advantage: Canada's Federal Court as a Venue for Pharmaceutical Patent Litigation

Latest Insights

Repudiation by Denied Access: ONCA Confirms Loss of Essential Common Area Access May Be Repudiatory Breach of Lease

Life Sciences Outlook 2026

The Life Sciences Boom: H2 2026 Outlook

Ontario Court Sets Aside ICSID Award in NAFTA Arbitration: Key Lessons on Jurisdiction and Arbitrator Impartiality

Stay Informed. Stay Ahead.